CLOs on the Move


 
Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients. Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.insysrx.com
  • 1333 South Spectrum Boulevard Suite 100
    Chandler, AZ USA 85286
  • Phone: 602.910.2617

Executives

Name Title Contact Details
Sanga Emmanuel
VP - Chief Compliance Officer Profile
Mollie Roth
Director of Compliance Profile
Mark Nance
Chief Legal Officer and General Counsel Profile
Mark Nance
Chief Legal Officer and General Counsel Profile

Similar Companies

Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator supporting customers from candidate selection to commercial launch.

Maitri Medicinals

Maitri Medicinals cultivates, produces and dispenses quality medical marijuana products to patients in Pittsburgh and Uniontown Pennsylvania who suffer from qualifying medical conditions and diseases.

North Bend Medical Center

NBMC is a multi-specialty, regional medical center with more than 400 employees and 70 medical providers representing approximately 20 specialties

New Age Medical Center

New Age Medical Center Functional Medicine plays a vital role in our everyday lives and Dr. Moreno is committed to helping our patients achieve improved overall wellness. In addition to internal medicine, anti-aging procedures, and nutritional & wei...

Deciphera

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the effectiveness of many cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. Deciphera has developed a diverse pipeline of drug candidates designed to improve outcomes for patients with cancer by enhancing the quality, rate and/or durability of their responses to treatment.